GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Subscribe To Our Newsletter & Stay Updated